Galmed Pharmaceuticals Ltd. Stock

$1.82

0.55% yesterday

Nasdaq, Jul 21, 10:17 pm CET

ISIN

IL0011313900

Symbol

GLMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Galmed Pharmaceuticals Ltd. Stock price

$1.82

-880.18 99.79% 5Y

Nasdaq, Closing price Mon, Jul 21 2025

-0.01 0.55%

ISIN

IL0011313900

Symbol

GLMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$4.1m

Enterprise Value

$-11.6m

Net debt

positive

Cash

$15.7m

Shares outstanding

2.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

2.2

P/B

0.2

Financial Health

Equity Ratio

88.3%

Return on Equity

-46.1%

ROCE

-43.2%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-7.2m | -

EBIT

$-7.3m | $-5.8m

Net Income

$-7.4m | $-7.5m

Free Cash Flow

$-5.2m

EPS

$-4.1

FCF per Share

$-2.3

Short interest

3.1%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Get Started for Free Today

Galmed Pharmaceuticals Ltd. Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Galmed Pharmaceuticals Ltd. forecast:

3x Hold

50%

3x Sell

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Galmed Pharmaceuticals Ltd. forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Galmed Pharmaceuticals Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.17 3.17	16% 16% -
- Research and Development Expense	2.98 2.98	4% 4% -
EBITDA	-7.21 -7.21	5% 5% -
- Depreciation and Amortization	0.07 0.07	133% 133% -
EBIT (Operating Income) EBIT	-7.28 -7.28	6% 6% -
Net Profit	-7.35 -7.35	16% 16% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Galmed Pharmaceuticals Ltd. Stock News

Neutral

PRNewsWire

●

about 2 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.

Neutral

PRNewsWire

●

2 months ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments.

Neutral

PRNewsWire

●

3 months ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models. The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.

More Galmed Pharmaceuticals Ltd. News

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Head office	Israel
CEO	Allen Baharaff
Employees	5
Founded	2000
Website	www.galmedpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now